文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA与GPRC5D双特异性抗体治疗复发难治多发性骨髓瘤的系统评价与荟萃分析

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.
PubMed 文献 · Br J Haematol · 2026-09-02

在推荐2期剂量下,两组总缓解率分别为65%与70%,疗效相当;GPRC5D组任何级别细胞因子释放综合征更常见(57% vs. 74%,p=0.006),但≥3级CRS及其他严重毒性 broadly 相当。既往五药暴露和更多治疗线数是缓解的负向调节因素。

要点

  • BCMA与GPRC5D双特异性抗体在RRMM中疗效相当,ORR分别为65%和70%。
  • GPRC5D组任何级别CRS更常见(74% vs. 57%,p=0.006),≥3级CRS无显著差异。
  • 既往五药暴露、更多治疗线数及既往BCMA靶向治疗降低缓解率。

核心结论

  • BCMA与GPRC5D靶向双特异性抗体在复发难治多发性骨髓瘤中显示可比疗效。
  • 常见非靶点特异性不良事件的安全性特征总体相当。
  • 缓解主要受治疗史影响。

研究设计与样本

  • 采用随机效应模型合并疗效与安全性结局,并行meta回归识别研究水平调节因素。

主要发现

  • 在推荐2期剂量下,BCMA与GPRC5D双特异性抗体的总缓解率分别为65%(95%CI 60%-70%)和70%(95%CI 66%-73%)。
  • ≥非常好的部分缓解率和完全缓解率两组相似。
  • 任何级别细胞因子释放综合征在GPRC5D组更频繁(57% vs. 74%,p=0.006)。
  • ≥3级CRS、神经毒性、感染和血液学不良事件两组 broadly 相当。
  • Meta回归显示既往五药暴露和更高中位治疗线数是缓解的负向调节因素,既往BCMA靶向治疗与BCMA靶向队列疗效降低相关。

临床怎么用

  • BCMA与GPRC5D双特异性抗体均可作为RRMM的有效选择,需结合治疗史个体化选择。
  • GPRC5D双特异性抗体使用时需关注任何级别CRS的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) or G protein-coupled receptor, class C, group 5, member D (GPRC5D) represent effective options for relapsed or refractory multiple myeloma (RRMM), yet direct comparative evidence remains limited. We performed a systematic review and meta-analysis of studies evaluating BCMA- or GPRC5D-targeted BsAbs in RRMM. Thirty studies comprising 3218 patients were included. Random-effects models were used to pool efficacy and safety outcomes, followed by meta-regression to identify study-level moderators of response. At the recommended phase 2 dose, BCMA- and GPRC5D-targeted BsAbs showed comparable efficacy, with overall response rates (ORRs) of 65% (95% confidence interval [CI], 60%-70%) and 70% (95% CI, 66%-73%) respectively. Rates of ≥very good partial response and complete response were also similar. Any-grade cytokine release syndrome (CRS) was more frequent with GPRC5D BsAbs (57% vs. 74%, p = 0.006), whereas grade ≥3 CRS and other severe toxicities, including neurotoxicity, infections and haematological adverse events (AEs), were broadly comparable. Meta-regression identified prior penta-drug exposure and higher median lines of therapy as negative moderators of response, with prior BCMA-directed therapy further associated with reduced efficacy in BCMA-targeted cohorts. Overall, BCMA- and GPRC5D-targeted BsAbs demonstrated comparable efficacy. Among the commonly reported non-target specific AEs, the safety profile was broadly comparable. The response appeared to be influenced primarily by treatment history.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Liang Q, Liu S, Li C, et al. BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection. Br J Haematol. 2026. PMID: 42687264. doi:10.1111/bjh.70824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。